1-3 of 3
Vivien Jacobs
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors

Free
Barry R. Davies, Nin Guan, Armelle Logie, Claire Crafter, Lyndsey Hanson, Vivien Jacobs, Neil James, Philippa Dudley, Kelly Jacques, Brendon Ladd, Celina M. D'Cruz, Michael Zinda, Justin Lindemann, Makoto Kodaira, Kenji Tamura, Emma L. Jenkins
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2015) 14 (11): 2441–2451.
https://doi.org/10.1158/1535-7163.MCT-15-0230
Published: 03 November 2015
View article titled, Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors
Open the PDF for Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors in another window
Includes: Supplementary data
Journal Articles

Abstract A109: AZD9291: an irreversible, potent and selective third generation tyrosine kinase inhibitor (TKI) targeting EGFR activating (EGFRm+) and resistance (T790M) mutations in advanced lung adenocarcinoma.

Free
Darren Cross, Sue Ashton, Caroline Nebhan, Cath Eberlein, M. Raymond V. Finlay, Gareth Hughes, Vivien Jacobs, Martine Mellor, Monica Red Brewer, Catherine Meador, Jonathon Orme, Paula Spitzler, Steve Powell, Amar Rahi, Paula Taylor, Richard A. Ward, Paula Daunt, Anne Galer, Teresa Klinowska, Graham Richmond, William Pao
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): A109.
https://doi.org/10.1158/1535-7163.TARG-13-A109
Published: 01 November 2013
View article titled, Abstract A109: AZD9291: an irreversible, potent and selective third generation tyrosine kinase inhibitor (TKI) targeting EGFR activating (EGFRm+) and resistance (T790M) mutations in advanced lung adenocarcinoma.
Journal Articles

Abstract C50: Molecular segmentation of high-risk prostate cancer by PTEN loss, AR upregulation, and TMPRSS2-ERG gene fusion.

Free
Vivien Jacobs, Chris Fitzpatrick, Victoria Williams, Marie Cumberbatch, Gillian Dalgliesh, Emma Donald, Chris Womack, Barry Davies, Neil Smith
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): C50.
https://doi.org/10.1158/1535-7163.TARG-11-C50
Published: 12 November 2011
View article titled, Abstract C50: Molecular segmentation of high-risk prostate cancer by PTEN loss, AR upregulation, and TMPRSS2-ERG gene fusion.